Wes Salomon
About Wes Salomon
Wes Salomon is a Director at Tessera Therapeutics, where he has worked since 2021. He has a strong background in RNA therapeutics, having held various roles in prominent biotechnology companies and earned a Ph.D. from UMass Medical School.
Current Role at Tessera Therapeutics
Wes Salomon currently serves as the Director at Tessera Therapeutics, a position he has held since 2021. He is based in Cambridge, Massachusetts. In this role, he oversees various projects and initiatives related to the company's focus on genetic medicines. His leadership contributes to the advancement of innovative therapeutic strategies within the organization.
Previous Experience at Tessera Therapeutics
Prior to his current role, Wes Salomon worked at Tessera Therapeutics in several capacities. He served as Associate Director from 2020 to 2021 and as Principal Scientist from 2019 to 2020. His experience at Tessera Therapeutics has provided him with a strong foundation in the development of genetic therapies.
Experience at Intellia Therapeutics, Inc.
Wes Salomon held multiple roles at Intellia Therapeutics, Inc. from 2016 to 2019. He began as Scientist II for 11 months, then advanced to Senior Scientist for one year, and finally served as Principal Scientist for another year. His work at Intellia Therapeutics focused on the development of CRISPR-based therapies, contributing to the company's research initiatives.
Education and Expertise
Wes Salomon earned his Doctor of Philosophy (Ph.D.) from the University of Massachusetts Medical School, where he studied from 2009 to 2015. He also holds a Master of Liberal Arts (ALM) from Harvard University, achieved between 2006 and 2008, and a Bachelor of Science (B.S.) from Worcester Polytechnic Institute, completed from 2001 to 2005. His academic background provides him with a strong foundation in molecular biology and RNA therapeutics.
Research Contributions and Publications
Wes Salomon has published research in peer-reviewed journals and presented at conferences, focusing on RNA interference (RNAi) technologies. He co-discovered sd-rxRNA®, a platform technology that enhances the stabilization and delivery of small RNAs, which is integral to RNAi applications in oncology. His thesis research on Argonaute kinetics has improved the understanding of small RNAs in the RNAi pathway.